跳至主要内容
临床试验/NL-OMON20070
NL-OMON20070尚未招募不适用

Role of cerebral blood flow pulsatility in hypertension related brain damage

Maastricht University Medical Center0 个研究点目标入组 75 人开始时间: 待定最近更新:

试验速览

阶段
不适用
状态
尚未招募
入组人数
75

研究概览

简要总结

暂无简介。

研究设计

研究类型
Observational

入排标准

入选标准

  • Criteria for the hypertensive group without known brain damage:
  • - Age 40-75 years
  • - Essential hypertension, defined as an ambulant blood pressure of = 130 over 80 mmHg.
  • Criteria for the hypertensive group with diagnosed brain damage (Fazekas=2):
  • - Age 40-75 years
  • - Essential hypertension, defined as an ambulant blood pressure of = 130 over 80 mmHg.
  • - Extensive white matter lesions: Fazekas score = 2, indicated on brain MRI.
  • Criteria for the control (normotensive) group:
  • - Age 40-75 years
  • - Normotensive (ambulant blood pressure of < 130 over 80 mmHg).

排除标准

  • - White coat hypertension
  • - Inability to stop antihypertensive medication (since this results in an altered blood pressure, not the original blood pressure before the use of medication.)
  • - Indication of history-taking, physical examination or routine laboratory tests of secondary hypertension
  • - Chronic renal insufficiency (eGFR<30 mL/min)
  • - Diabetes mellitus
  • - Ischemic or valvular heart disease or electrocardiographic evidence of atrial fibrillation
  • - Transient ischemic attacks and ischemic or hemorrhagic stroke
  • - Obstructive sleep apnea syndrome
  • - Systemic inflammation, such as active rheumatoid arthritis
  • - Body Mass Index > 32 kg/m²
  • - Inability to provide informed consent
  • - Any contraindication for MRI: metallic implants, pacemaker, claustrophobia, pregnancy, tattoos in the head/neck region, permanent make-up.
  • - Contraindications for the gadolinium-containing contrast agent: allergic reaction, eGFR<30 mL/min

研究者

相似试验